Tonix Pharmaceuticals Holding Corp. (TNXP) financial statements (2021 and earlier)

Company profile

Business Address 28 MAIN STREET
CHATHAM, NJ 07928
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments77565531111012
Cash and cash equivalents77565531111012
Prepaid expense2      
Other undisclosed current assets9633322
Total current assets:88625833141214
Noncurrent Assets
Operating lease, right-of-use asset1100001
Property, plant and equipment9400000
Intangible assets, net (including goodwill)0000000
Intangible assets, net (excluding goodwill)0000000
Restricted cash and investments0000000
Other undisclosed noncurrent assets0 00  0
Total noncurrent assets:10611111
TOTAL ASSETS:98685834151215
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5231311
Accounts payable5231311
Debt    000
Other undisclosed current liabilities5311211
Total current liabilities:10453522
Noncurrent Liabilities
Long-term debt and lease obligation1100000
Operating lease, liability1100000
Other undisclosed noncurrent liabilities(1)(1)(0)(0)   
Total noncurrent liabilities: 100000
Total liabilities:11553522
Stockholders' equity
Stockholders' equity attributable to parent8863543191013
Common stock0000000
Additional paid in capital355313292256227218213
Accumulated other comprehensive loss(0)(0)(0)(0)(0)(0)(0)
Accumulated deficit(268)(251)(239)(224)(217)(208)(201)
Total stockholders' equity:8863543191013
TOTAL LIABILITIES AND EQUITY:98685834151215

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Operating expenses(17)(12)(14)(7)(9)(8)(6)
Other undisclosed operating income      0
Operating loss:(17)(12)(14)(7)(9)(8)(6)
Nonoperating income
(Investment Income, Nonoperating)
0000000
Net loss attributable to parent:(17)(12)(14)(7)(9)(8)(6)
Preferred stock dividends and other adjustments   (1)   
Other undisclosed net loss available to common stockholders, basic   (0)(2)  
Net loss available to common stockholders, diluted:(17)(12)(14)(9)(11)(8)(6)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(17)(12)(14)(7)(9)(8)(6)
Other comprehensive income (loss) (0)00 0 
Other undisclosed comprehensive income0   0  
Comprehensive loss:(17)(12)(14)(7)(9)(8)(6)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0(0)(0)(0)(0) 
Comprehensive loss, net of tax, attributable to parent:(17)(12)(14)(7)(9)(8)(6)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: